Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 7 hours ago
Olympus pushes deeper into oncology with $270M BioProtect deal
about 7 hours ago
Olympus is pushing deeper into prostate cancer care with the acquisition of...
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
about 7 hours ago
Amid an intensifying debate over how Washington should counter China’s rapid ascent...
Makary’s FDA reforms ‘continue to move forward’ despite leadership turmoil
about 12 hours ago
As the FDA adjusts to life without Marty Makary, M.D., who resigned...
Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential
about 13 hours ago
Kura Oncology has published early data on darlifarnib in combination with Bristol...
Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues
about 14 hours ago
Eli Lilly has splashed up to $3.8 billion on an infectious disease...
Facing looming Xtandi patent cliff, Astellas pins hopes on more deals while still cutting costs
about 15 hours ago
Faced with a future of evaporating Xtandi sales, Astellas has set out...
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
1 day ago
Eli Lilly is laying the groundwork for a phase 2 trial of...
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
5 days ago
Recorded at Fierce Biotech Week in Boston, this episode of “The Top...
Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both
5 days ago
It’s been more than four years since Novartis shook up the CAR-T...
OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win
5 days ago
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate...
Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop
5 days ago
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate...
Chutes & Ladders—Former FDA leader takes new biotech Turn
5 days ago
Stephen Hahn, M.D., who served as the commissioner of the FDA for...